Médecine

Paramédical

Autres domaines


S'abonner

Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a - 28/08/20

Doi : 10.1016/j.biopha.2020.110436 
Jie Zhao a, , 1 , Xiaodong Yang b, 1, Chenghua Wang a, Shuai Song c, Kun Cao d, Taohua Wei e, Qiaoxue Ji a, Wanqun Zheng a, Jiali Li a, Xue Zhou a, Jie Liu f
a Department of Chinese Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China 
b Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China 
c Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China 
d Department of Orthopaedic, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China 
e Department of Neurology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230022, China 
f Institute for Medical Virology, Goethe University Frankfurt am Main, Frankfurt 60596, Germany 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Highlights

The data derive from Chinese medicine prescription according to the fifth National recommendations during the SARS-CoV pandemics.
The alterations of inflammatory agents, immune function and leukocyte differential count in severe pneumonia of SARS-COV-2 patients after yidu-toxicity blocking lung decoction was given.
The inflammatory agents, IL-6 and TNF-α,was found to be decreased by Yidu-toxicity blocking lung decoction in vitro observations.
Yidu-toxicity blocking lung decoction could relieving inflammation of SARS-COV-2 patients and offering anther option in clinical settings.

Le texte complet de cet article est disponible en PDF.

Abstract

The present study investigates the differences in inflammatory agents alterations, immune function, and leukocyte differential count evaluation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome after the recommended Chinese medicine prescription of Yidu-toxicity blocking lung decoction. A total of 40 patients with yidu-toxicity blocking lung syndrome, diagnosed as severe pneumonia of SARS-COV-2 following the latest Chinese national recommendations for the diagnosis and treatment of pneumonia caused by SARS-COV-2 (the 5th edition), were recruited. They were randomly divided into the pure western medicine therapy group (PWM) and integrated into Chinese and Western medicine therapy group (ICW). The general strategies were given to both groups according to the national recommendations, and the ICW group was given Yidu-toxicity blocking lung decoction extraorally. A radioimmunoassay method was adopted to detect the content of IL-6, IL-8,IL-2R,TNF-α, procalcitonin (PCT) and high-sensitivity C-reactive protein (hs-CRP) in sera. Flow cytometry was used to determine the peripheral blood lymphocyte subsets (the levels of CD3+, CD4+, CD8+, and the ratios of CD4+/CD8+). The white blood cell counts (WBC#), neutrophils count(N#), and lymphocyte counts (L#) were measured using a fully automatic blood rheological instrument. The t-test or Rank Sum Test and Spearman analysis were conducted to evaluate the differences. The results showed that IL-6 (P = 0.013) and TNF-α (P = 0.035) levels in the PWM group were significantly higher than those in the ICW group after treatment. Infection related indicators such as WBC#, N#, L#, hs-CRP showed no differences. The analysis showed that there was no statistical difference in the values of CD4 and CD8 between the two groups. By the end of Day 29, all patients were discharged and the final cure rate for both group were 100 %.

Taken together, we conclude that Yidu-toxicity blocking lung decoction could relieve inflammation of SARS-COV-2 patients with yidu-toxicity blocking lung syndrome by eliminating inflammatory agents. CM can serve as a complementary medication to western medicine, which should be highlighted in clinical settings.

Le texte complet de cet article est disponible en PDF.

Keywords : SARS-COV-2, Chinese medicine, Clinical treatment


Plan


© 2020  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 129

Article 110436- septembre 2020 Retour au numéro
Article précédent Article précédent
  • Anti-ischemia/reperfusion injury effects of notoginsenoside R1 on small molecule metabolism in rat brain after ischemic stroke as visualized by MALDI–MS imaging
  • Ting Zhu, Lei Wang, Fang Tian, Xin Zhao, Xiao-Ping Pu, Gui-Bo Sun, Xiao-Bo Sun
| Article suivant Article suivant
  • Serum proteomics analysis of candidate predictive biomarker panel for the diagnosis of trastuzumab-based therapy resistant breast cancer
  • Ting Yang, Ziyi Fu, Yin Zhang, Min Wang, Changfei Mao, Weihong Ge

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.